Weaver Capital Management LLC Has $1.25 Million Stock Holdings in Stryker Co. (NYSE:SYK)

Weaver Capital Management LLC raised its holdings in Stryker Co. (NYSE:SYK) by 48.0% during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 3,471 shares of the medical technology company’s stock after purchasing an additional 1,125 shares during the quarter. Weaver Capital Management LLC’s holdings in Stryker were worth $1,254,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of the business. Liberty Capital Management Inc. boosted its holdings in shares of Stryker by 2.7% in the 3rd quarter. Liberty Capital Management Inc. now owns 11,543 shares of the medical technology company’s stock valued at $4,170,000 after purchasing an additional 301 shares in the last quarter. GAM Holding AG boosted its holdings in shares of Stryker by 7.1% in the 3rd quarter. GAM Holding AG now owns 10,787 shares of the medical technology company’s stock valued at $3,897,000 after purchasing an additional 714 shares in the last quarter. Private Advisor Group LLC boosted its holdings in shares of Stryker by 3.4% in the 3rd quarter. Private Advisor Group LLC now owns 15,967 shares of the medical technology company’s stock valued at $5,768,000 after purchasing an additional 526 shares in the last quarter. BLB&B Advisors LLC boosted its holdings in shares of Stryker by 3.3% in the 3rd quarter. BLB&B Advisors LLC now owns 38,564 shares of the medical technology company’s stock valued at $13,932,000 after purchasing an additional 1,245 shares in the last quarter. Finally, Stanley Laman Group Ltd. boosted its holdings in shares of Stryker by 83.4% in the 3rd quarter. Stanley Laman Group Ltd. now owns 1,379 shares of the medical technology company’s stock valued at $498,000 after purchasing an additional 627 shares in the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on SYK. Morgan Stanley raised their target price on Stryker from $345.00 to $350.00 and gave the company an “equal weight” rating in a report on Monday, July 15th. Truist Financial raised their price objective on Stryker from $345.00 to $370.00 and gave the company a “hold” rating in a report on Monday, October 14th. Wolfe Research began coverage on Stryker in a report on Tuesday, September 10th. They set an “outperform” rating and a $405.00 price objective on the stock. Stifel Nicolaus cut their price objective on Stryker from $375.00 to $365.00 and set a “buy” rating on the stock in a report on Wednesday, July 31st. Finally, Needham & Company LLC raised their price objective on Stryker from $392.00 to $393.00 and gave the company a “buy” rating in a report on Thursday, August 1st. Four equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $381.16.

Insider Buying and Selling

In related news, VP M Kathryn Fink sold 7,347 shares of the company’s stock in a transaction that occurred on Tuesday, September 17th. The stock was sold at an average price of $366.98, for a total transaction of $2,696,202.06. Following the transaction, the vice president now directly owns 10,042 shares of the company’s stock, valued at approximately $3,685,213.16. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, insider Viju Menon sold 600 shares of the company’s stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $355.00, for a total transaction of $213,000.00. Following the transaction, the insider now directly owns 9,069 shares of the company’s stock, valued at approximately $3,219,495. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP M Kathryn Fink sold 7,347 shares of the stock in a transaction that occurred on Tuesday, September 17th. The stock was sold at an average price of $366.98, for a total value of $2,696,202.06. Following the completion of the sale, the vice president now directly owns 10,042 shares of the company’s stock, valued at approximately $3,685,213.16. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 220,068 shares of company stock valued at $71,811,372. 5.90% of the stock is owned by company insiders.

Stryker Stock Down 0.3 %

Shares of NYSE:SYK opened at $366.20 on Wednesday. The company has a market capitalization of $139.50 billion, a price-to-earnings ratio of 41.80, a P/E/G ratio of 2.85 and a beta of 0.91. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.68 and a quick ratio of 0.95. The business’s 50-day moving average is $357.37 and its 200-day moving average is $343.45. Stryker Co. has a 1 year low of $255.22 and a 1 year high of $374.63.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Tuesday, July 30th. The medical technology company reported $2.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.79 by $0.02. The company had revenue of $5.42 billion for the quarter, compared to the consensus estimate of $5.40 billion. Stryker had a return on equity of 22.89% and a net margin of 16.12%. The firm’s revenue was up 8.5% compared to the same quarter last year. During the same period in the previous year, the business earned $2.54 EPS. Equities research analysts predict that Stryker Co. will post 12 earnings per share for the current year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 31st. Investors of record on Monday, September 30th will be paid a dividend of $0.80 per share. This represents a $3.20 dividend on an annualized basis and a yield of 0.87%. The ex-dividend date is Monday, September 30th. Stryker’s dividend payout ratio (DPR) is currently 36.53%.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.